Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GMED 
Globus Medical (GMED)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: GMED (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $82.55
1 Year Target Price $82.55
| 4 | Strong Buy |
| 5 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 21.03% | Avg. Invested days 52 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.11B USD | Price to earnings Ratio 23.26 | 1Y Target Price 82.55 |
Price to earnings Ratio 23.26 | 1Y Target Price 82.55 | ||
Volume (30-day avg) 14 | Beta 1.2 | 52 Weeks Range 51.79 - 94.93 | Updated Date 08/15/2025 |
52 Weeks Range 51.79 - 94.93 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate 0.76 | Actual 0.86 |
Profitability
Profit Margin 13.58% | Operating Margin (TTM) 17.33% |
Management Effectiveness
Return on Assets (TTM) 5.82% | Return on Equity (TTM) 8.62% |
Valuation
Trailing PE 23.26 | Forward PE 18.76 | Enterprise Value 7997793964 | Price to Sales(TTM) 3.09 |
Enterprise Value 7997793964 | Price to Sales(TTM) 3.09 | ||
Enterprise Value to Revenue 3.05 | Enterprise Value to EBITDA 12.9 | Shares Outstanding 112627000 | Shares Floating 111731510 |
Shares Outstanding 112627000 | Shares Floating 111731510 | ||
Percent Insiders 0.69 | Percent Institutions 102.33 |
Upturn AI SWOT
Globus Medical
Company Overview
History and Background
Globus Medical was founded in 2003 with a focus on developing innovative solutions for musculoskeletal disorders. It has grown organically and through acquisitions, expanding its product portfolio and geographic reach. Globus Medical became a public company in 2012.
Core Business Areas
- Spine: Globus Medical's spine division focuses on the design, development, and commercialization of spinal implants, instruments, and enabling technologies for various spinal disorders.
- Trauma: This segment develops and markets products for the treatment of fractures and other traumatic injuries to the musculoskeletal system.
- Robotics and Navigation: Focuses on surgical robots (ExcelsiusGPS) and navigation systems to improve the precision and efficiency of surgical procedures.
- Enabling Technologies: Develops surgical tools, navigation and imaging platforms such as ExcelsiusGPS that are used to make surgical procedures safer and improve patient outcomes.
Leadership and Structure
Daniel Scavilla serves as the CEO. The company has a traditional corporate structure with departments such as R&D, marketing, sales, and operations.
Top Products and Market Share
Key Offerings
- ExcelsiusGPS: A robotic navigation platform used in spine surgery. It enhances accuracy and reduces radiation exposure. Competitors include Medtronic's Mazor X Stealth Edition and Stryker's Mako system. Globus has been gaining market share with ExcelsiusGPS.
- REFLEXX Plate System: REFLEXX Plate System is a sternal fixation system designed to stabilize the sternum following median sternotomy. Competitors include Zimmer Biomet and DePuy Synthes.
- CREO MIS Expandable Pedicle Screw System: A minimally invasive pedicle screw system designed to provide stability and fusion in spinal procedures. Competitors include Medtronic's CD Horizon Solera Voyager and Nuvasive's Reline system.
Market Dynamics
Industry Overview
The musculoskeletal device market is driven by an aging population, increasing prevalence of spinal disorders and trauma cases, and technological advancements. The market is competitive, with large players and smaller, innovative companies.
Positioning
Globus Medical is positioned as a technology-driven innovator in the musculoskeletal space. It has strong growth in robotic surgery and enabling technologies.
Total Addressable Market (TAM)
The global musculoskeletal device market is estimated to be over $50 billion. Globus Medical is well-positioned to capture a significant portion of this market due to its focus on innovative technologies, especially robotics.
Upturn SWOT Analysis
Strengths
- Innovative Product Portfolio
- Strong Growth in Robotics
- Vertically Integrated Manufacturing
- Strong Sales Force
- Consistent R&D Investment
Weaknesses
- High reliance on spine market
- Limited presence in certain international markets
- Vulnerable to reimbursement changes
- Smaller than major competitors
Opportunities
- Expanding robotic surgery adoption
- Developing new enabling technologies
- Increasing international sales
- Acquiring complementary businesses
- Entering new market segments (e.g. shoulder, hip)
Threats
- Intense competition
- Pricing pressures
- Regulatory changes
- Product liability lawsuits
- Economic downturns
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Stryker (SYK)
- Johnson & Johnson (JNJ)
- Nuvasive (NUVA)
- Zimmer Biomet (ZBH)
Competitive Landscape
Globus Medical competes with larger, more established companies. Its strengths lie in its innovative product portfolio and dedicated sales force. Its smaller size can be a disadvantage in terms of resources and brand recognition.
Major Acquisitions
Quandary Medical
- Year: 2018
- Acquisition Price (USD millions): 40
- Strategic Rationale: Expanded Globus Medical's portfolio in the interventional pain management market.
Growth Trajectory and Initiatives
Historical Growth: Globus Medical has experienced strong revenue growth over the past decade, driven by its innovative product portfolio and expanding sales force.
Future Projections: Analysts project continued revenue growth for Globus Medical, driven by increasing adoption of robotic surgery and its expansion into new market segments.
Recent Initiatives: Recent strategic initiatives include the continued launch of new robotic surgery applications and development of its enabling technology platform.
Summary
Globus Medical is a strong competitor in the musculoskeletal device market, particularly in spine and robotics. Its innovative products and focused sales strategy contribute to its growth. However, it faces intense competition and must continue to invest in R&D and international expansion to maintain its position. The company's growth in robotics is a significant strength.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst estimates
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Globus Medical
Exchange NYSE | Headquaters Audubon, PA, United States | ||
IPO Launch date 2012-08-03 | CEO, President & Director Mr. Keith W. Pfeil | ||
Sector Healthcare | Industry Medical Devices | Full time employees 5300 | Website https://www.globusmedical.com |
Full time employees 5300 | Website https://www.globusmedical.com | ||
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip and knee joint solutions, including modular hip stems and acetabular cups for total hip arthroplasty, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants; and neuromonitoring services, which provides onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also offers enabling technologies, such as imaging, navigation, and robotics (INR) solutions for assisted surgery, which includes the ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures with screw and interbody spacer placement applications; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative, image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.